Sangamo enters into asset sale agreements with Lilly and Astellas

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

ZF-transcription factors for Prion Disease

“Engineered zinc finger protein transcription factors potently reduce brain PrP expression and extend survival in prion-infected mice”
Bryan Zeitler et al.
This is a post-conference recording of a presentation given at the Prion 2022 conference on September 16, 2022 by Bryan Zeitler, Senior Director, Gene Regulation at Sangamo Therapeutics.